11.22.2023
In response to a recent shortage of Beyfortus (Nirsevimab) — a long-acting monoclonal antibody for prevention of severe RSV among infants and children — the CDC has announced the release of 77,000 additional doses for hospitals and providers.
Nirsevimab may be given in child's 1st year. Another dose can be given during their 2nd RSV season for some high-risk patients. The CDC does not recommend Nirsevimab for most infants born to a mother who received maternal RSV vaccine, except for infants where <14 days have elapsed between vaccination and birth.
For additional guidance on prescribing Nirsevimab, read AAP's Nirsevimab FAQs.